TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment

Oncotarget

Volumn 7, Issue 28, 2016, Pages 44534-44544

  Wu, Meng ^a,b   Chen, Xian ^a,b   Lou, Jianfang ^a,b   Zhang, Shuping ^a   Zhang, Xiaojie ^a,b   Huang, Lei ^a,b   Sun, Ruihong ^a,b   Huang, Peijun ^a,b   Wang, Fang ^a,b   Pan, Shiyang ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b National Key Clinical Department of Laboratory Medicine   (China)

Author keywords

CD8+ Treg; Ovarian cancer; P38 MAPK; TGF 1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; CD8 ANTIGEN; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; REGULATORY T LYMPHOCYTE; SUPERNATANT; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; AGED; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENETICS; MAPK SIGNALING; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; CD8 ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MICROENVIRONMENT;

EID: 84978696412     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10003     Document Type: Article

References (35)

1. Brtnicky T, Fialova A, Lastovicka J, Rob L and Spisek R. Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients. Hum Immunol. 2015; 76: 187-191.
2. Preston CC, Goode EL, Hartmann LC, Kalli KR and Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy; 2011, 3: 539-556.
3. Charbonneau B, Goode EL, Kalli KR, Knutson KL and Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33: 137-164.
4. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer research, 2012; 72: 2162-2171.
5. Zhang S, Ke X, Zeng S, Wu M, Lou J, Wu L, Huang P, Huang L, Wang F and Pan S. Analysis of CD8(+) Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cell Mol Immunol. 2015; 12: 580-591.
6. Wei T, Zhang J, Qin Y, Wu Y, Zhu L, Lu L, Tang G and Shen Q. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Cancer Res. 2015; 5: 2190-2201.
7. Huang XM, Liu XS, Lin XK, Yu H, Sun JY, Liu XK, Chen C, Jin HL, Zhang GE, Shi XX, Zhang Q and Yu JR. Cancer Sci. 2014; 105: 150-158.
8. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102: 18538-18543.
9. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24: 5373-5380.
10. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL and Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS one. 2013; 8: e80063.
11. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL and Goode EL. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer immunology, immunotherapy. 2015.
12. Alvarez Arias DA, Kim HJ, Zhou P, Holderried TA, Wang X, DranoffG and Cantor H. Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol Res. 2014; 2: 207-216.
13. Li J, Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ, Chen QY, He J, Chen SP, Zheng LM, Qian CN and Zeng YX. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma. J Transl Med. 2011; 9: 189.
14. Song G, Wang X, Jia J, Yuan Y, Wan F, Zhou X, Yang H, Ren J, Gu J and Lyerly HK. Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother. 2013; 62: 1123-1130.
15. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y and Zheng P. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16: 336-346.
16. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ and Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13: 6947-6958.
17. Chen W, Wahl SM. TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun. 2002; 5: 62-91.
18. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood; 2006; 108: 804-811.
19. Csencsits K, Wood SC, Lu G and Bishop DK. Transforming growth factor-beta1 gene transfer is associated with the development of regulatory cells. Am J Transplant. 2005; 5: 2378-2384.
20. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR and Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004; 172: 5149-5153.
21. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G and Wahl SM. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198: 1875-1886.
22. Peng Y, Laouar Y, Li MO, Green EA and Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A. 2004; 101: 4572-4577.
23. Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X and Feng M. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. J Surg Oncol. 2013, 107: 422-427.
24. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C and Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9: 139-148.
25. Ji F, Fu SJ, Shen SL, Zhang LJ, Cao QH, Li SQ, Peng BG, Liang LJ and Hua YP. The prognostic value of combined TGF-beta1 and ELF in hepatocellular carcinoma. BMC cancer. 2015; 15: 116.
26. Cannon MJ, Goyne HE, Stone PJ, Macdonald LJ, James LE, Cobos E and Chiriva-Internati M. Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer immunology, immunotherapy; 2013, 62: 839-849.
27. Mougiakakos D, Choudhury A, Lladser A, Kiessling R and Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010; 107: 57-117.
28. Dandawate S, Williams L, Joshee N, Rimando AM, Mittal S, Thakur A, Lum LG and Parajuli P. Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-beta1 activity. Cancer Immunol Immunother. 2012, 61: 701-711.
29. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT and Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007; 13: 4345-4354.
30. Li X, Ye F, Chen H, Lu W, Wan X and Xie X. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer letters; 2007, 253: 144-153.
31. Eusebio M, Kuna P, Kraszula L, Kupczyk M and Pietruczuk M. Allergy-related changes in levels of CD8+CD25+FoxP3(bright) Treg cells and FoxP3 mRNA expression in peripheral blood: the role of IL-10 or TGFbeta. J Biol Regul Homeost Agents. 2014; 28: 461-470.
32. Park IK, Letterio JJ and Gorham JD. TGF-beta 1 inhibition of IFN-gamma-induced signaling and Th1 gene expression in CD4+ T cells is Smad3 independent but MAP kinase dependent. Mol Immunol. 2007; 44: 3283-3290.
33. Lu L, Wang J, Zhang F, Chai Y, Brand D, Wang X, Horwitz DA, Shi W and Zheng SG. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J Immunol. 2010; 184: 4295-4306.
34. Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, Lüth S, Blessing M, Herkel J and Schramm C. P38 MAP kinase signaling is required for the conversion of CD4+CD25-T cells into iTreg. PloS one. 2008; 3: e3302.
35. Adler HS, Kubsch S, Graulich E, Ludwig S, Knop J and Steinbrink K. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood. 2007; 109: 4351-4359.